REGENXBIO (RGNX)
(Delayed Data from NSDQ)
$11.93 USD
-0.38 (-3.09%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $11.95 +0.02 (0.17%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum F VGM
Brokerage Reports
REGENXBIO Inc. [RGNX]
Reports for Purchase
Showing records 1 - 20 ( 66 total )
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Rolling BLA Submission for RGX-121 Expected in 3Q24; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Financial Results Reported; Reiterate Buy; Increasing PT to $38
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Initial Ph1/2 DMD Data @ Higher RGX-202 Dose; Strength/Functional Data in H2:24
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Q4/FY23: RGX-202/DMD Update at MDA; ABBV-RGX-314 (SCS) Updates in 2024
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Rare Disease Pipeline wAMD Gene Therapy Competitor Updates; Reiterate NEUTRAL
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Ph2 ABBV-RGX-314 (SCS)/wAMD Trial Update; Eyes on Rare Disease Pipeline in 2024
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials Restructuring; 1yr Ph2 ALTITUDE Update for SCS-RGX-314/DR @ AAO
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology-The Wedbush Monthly Check-Up: November 2023
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
RGX-202 Showing Signs of Strength At WMS; Focus is on Functional Data in 2024
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A